We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test May Replace ELISA for Detecting Antibodies

By LabMedica International staff writers
Posted on 15 Apr 2019
A microwire-based test may replace enzyme-linked immunosorbent assay (ELISA) as the primary method to detect antibodies specific for pathogenic microorganisms in patient's sera.

Detection of viral infection is commonly performed using serological techniques like ELISA to detect antibody responses. More...
Such assays may also be used to determine the infection phase based on isotype (IgG or IgM) prevalence. However, ELISAs demonstrate limited sensitivity and are difficult to perform at the point of care.

Investigators at Colorado State University (Fort Collins, USA) have described a method for detecting antibodies against pathogenic viruses with sensitivity significantly better than ELISA. Their method reportedly enables label-free, rapid detection of ultra-low concentrations of virus specific antibodies.

The simple test comprised a capacitive biosensor that incorporated gold microwires coated with Zika or Chikungunya virus envelope antigen. An electrical current passed through the wire created a charge on the wire. Antibodies from the patient's sample bound to the viral proteins on the wire, which increased the outside mass. In addition, antibody binding increased the ability of the wire to hold the charge. By measuring the change in mass, it was possible to quantify the number of antibodies on the surface of the wire.

The investigators reported that with little discernable nonspecific binding, the sensor could detect as few as 10 antibody molecules in a small volume (30 microliters) of fluid within a few minutes. It could also be used to rapidly, specifically, and accurately determine the isotype of antigen-specific antibodies.

"This type of research project is something that none of us could do on our own," said senior author Dr. Brian Geiss, associate professor of microbiology, immunology, and pathology at Colorado State University. "We synergized our efforts to come up with new solutions to problems we are hoping will eventually be used in clinical settings. We hope that it can be used for point-of-care diagnostics, and that it can be developed into a compact hand-held system that can be used in the clinic or in resource-limited areas."

The microwire antibody detection method was described in the April 15, 2019, issue of the journal Biosensors and Bioelectronics.

Related Links:
Colorado State University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Manual Pipetting Aid
Pipette Controllers macro
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.